Navigation Links
Cephalon Presents Positive Results for Fentora in Breakthrough Pain,,,Associated with Neuropathic Conditions

mation on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products, including any future indications for FENTORA; interpretation of clinical results, including the results of the clinical trials of FENTORA in patients with neuropathic pain; prospects for regulatory approval; market prospects for its product; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward- looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:11/25/2008)...e recovery , , Audio and Web Video Resource...o Clinic News Blog. Please see the bottom of this ...nn., Nov. 25 A Mayo Cli...t think they,re having a stroke -- and as a result...worsens. The findings appear in the current issue ...
(Date:11/25/2008)... Nov. 25 Proteolix, Inc., a,leade...eutics that target,protein degradation pathways i... that data from two ongoing Phase 2 clinical trial...ented at the upcoming 50th Annual Meeting of the,... is the first in a new class,of specific proteaso...
(Date:11/25/2008)...nical Trial to Assess Survival of Patients Receivi...sectable Hepatocellular Carcinoma , , BELLE... Oncology, Inc. (LSO) today announced the completi...l of Light Infusion Therapy(TM) (Litx(TM)) as a tr...(HCC), also known as hepatoma or primary liver can...
(Date:11/24/2008)...RNewswire/ -- Domino,s Pizza (NYSE: DPZ ), the,...ing up to raise dough for,the kids of St. Jude Ch...,Thanks and Giving campaign. Domino,s customers w...int of purchase to benefit the children of St. Jud...hone or when ordering online at, www.dominos.com ...
Breaking Medicine Technology:Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 1July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 2July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 4Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 1Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 2Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 1Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 2Two New Jersey Hormone Therapy Lawsuits Dismissed 6534 1
...O VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AV... the presentation of,Phase III data, including eff... outcomes in patients with diabetic peripheral,neu...al drug,Zenvia(TM) (dextromethorphan/quinidine (DM...ist. The data were accepted as,late-breakers, and...
...RIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Arche...overing and developing,aptamers, announced the suc... aptamer therapeutic, ARC1779. ARC1779 is designed... aggregation of,platelets by inhibiting the bindin...tor on platelets. Activated vWF is scientifically,...
Other Medicine Technology:AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7Archemix Announces Completion of Phase 1 Trial of ARC1779 2Archemix Announces Completion of Phase 1 Trial of ARC1779 3
(Date:12/2/2008)...Resilient, Cost and Energy Efficient Information I... EMC Corporation (NYSE: EMC ), th...ions, today announced that the Daughters of Charit...ospitals spanning the California coast, has consol...s continuity functions to deliver new online clini...
(Date:12/2/2008)...valuate Efficacy of Commercially Available Hypomet...Dec. 2 Eisai Corporation of North ...the first clinical trial evaluating the activity o...o Vidaza(R) (azacitidine) in adult patients with i...splastic syndromes (MDS), a potentially life-threa...
(Date:12/2/2008)...arotz Dental is now one of only two dental,practi...ew Attachment,Procedure). This is the only laser...approved for new attachment of gum and bone tissue...sue, without removing healthy tissue, maintains,t...in and discomfort to the,patient, closes the peri...
(Date:12/2/2008)...Call/ -- Global Med Technologies(R), Inc.,("Globa...), an international,e-Health, medical information...opean subsidiary, Inlog S.A., has licensed its Edg...rveur" in France, to 21 Assistance Publique -,Hop...3,000 patient beds. For,Global Med, this project ...
Breaking Medicine News(10 mins):Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 3Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 4
...armaceuticals Inc (RPI) has received a tentative a...sinopril is recommended for hypertension, either a...anti-hypertenive agents. It is also used as adjunc...t failure and patients who do not respond to diure...
...s of drugs based on a widely used anticancer drug,...fects in the laboratory and in mice, according to ...eresting for the treatment of these tumors. // Pr...were extremely active in blocking the same cell ta...
...ro, Cipro. That's been the mantra of the media as ...ds who weren't -- clamor for the potent antibiotic...eaper and widely available medications can be used... penicillin. Although alternatives exist, Cipro is...
...ental anti-cancer drug has shown effectiveness in ...o a new report. Researchers say the drug probably ...seful for treating other types of cancer. Dr. Anto...esda, Maryland, and colleagues tested the drug, de...
Other Medicine News:
Standard reading test. "Clearing weather..."
Directional `E' and `C' test.
...These Low Contrast Flip charts contain 5 pages of ...ach page. Optotype size is 9.5M. Contrast levels a... can be used at several different distances. These...a different set of symbols to guard against memor...
...The PowerLab/4SP is a high-performance data acquis... applications including human and animal physiolog..., biochemistry, and biomedical engineering. The un...fast speeds (up to 200 000 samples per second cont...
Medicine Products: